AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the
Exchange Act of 1934
of Report (Date of Earliest event Reported): December 31, 2014
MEDICAL PHARMA, INC.|
|(Exact name of
registrant as specified in its charter)|
|(State or other
incorporation or organization)
BEVERLY GLEN CIRCLE, SUITE 301|
CA 90077 |
|(Address of principal
telephone number, including area code)|
|(Former name or
former address, if changed since last report)|
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Employment Agreement dated June 01, 2010 (the “Employment
Agreement”) between Kim Giffoni, who had served as the Company’s Executive Vice President of Foreign Sales and Investor
Relations, and Targeted Medical Pharma, Inc. (the “Company”) expired on December 31, 2014 (the “Separation Date”).
Mr. Giffoni will continue to serve as a Director of the Company.
Mr. Giffoni’s departure was not as a result of any disagreement
with the Company on any matter relating to the Company’s operations, policies or practices.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 7, 2015
||TARGETED MEDICAL PHARMA, INC.|
||/s/ William E. Shell|
||William E. Shell, MD|
||Chief Executive Officer |